Literature DB >> 15132542

Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris.

Bang Yeon Hwang1, Bao-Ning Su, Heebyung Chai, Qiuwen Mi, Leonardus B S Kardono, Johar J Afriastini, Soedarsono Riswan, Bernard D Santarsiero, Andrew D Mesecar, Robert Wild, Craig R Fairchild, Gregory D Vite, William C Rose, Norman R Farnsworth, Geoffrey A Cordell, John M Pezzuto, Steven M Swanson, A Douglas Kinghorn.   

Abstract

Two cytotoxic rocaglate derivatives possessing an unusual dioxanyloxy unit, silvestrol (1) and episilvestrol (2), were isolated from the fruits and twigs of Aglaia silvestris by bioassay-guided fractionation monitored with a human oral epidermoid carcinoma (KB) cell line. Additionally, two new baccharane-type triterpenoids, 17,24-epoxy-25-hydroxybaccharan-3-one (3) and 17,24-epoxy-25-hydroxy-3-oxobaccharan-21-oic acid (4), as well as eleven known compounds, 1beta,6alpha-dihydroxy-4(15)-eudesmene (5), ferulic acid (6), grasshopper ketone (7), apigenin, cabraleone, chrysoeriol, 1beta,4beta-dihydroxy-6alpha,15alpha-epoxyeudesmane, 4-hydroxy-3-methoxyacetophenone, 4-hydroxyphenethyl alcohol, ocotillone, and beta-sitosterol 3-O-beta-D-glucopyranoside, were also isolated and characterized. The structures of compounds 1-4 were elucidated by spectroscopic studies and by chemical transformation. The absolute stereochemistry of silvestrol (1) was established by a X-ray diffraction study of its di-p-bromobenzoate derivative, and the structure of 3 was also confirmed by single-crystal X-ray diffraction. The isolates and chemical transformation products were evaluated for cytotoxicity against several human cancer cell lines, and silvestrol (1) and episilvestrol (2) exhibited potent in vitro cytotoxic activity. Silvestrol (1) was further evaluated in vivo in the hollow fiber test and in the murine P-388 leukemia model.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15132542     DOI: 10.1021/jo040120f

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  68 in total

1.  Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies.

Authors:  Christina M Rodrigo; Regina Cencic; Stéphane P Roche; Jerry Pelletier; John A Porco
Journal:  J Med Chem       Date:  2011-12-19       Impact factor: 7.446

2.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

Review 3.  Potential of plant-derived natural products in the treatment of leukemia and lymphoma.

Authors:  David M Lucas; Patrick C Still; Lynette Bueno Pérez; Michael R Grever; A Douglas Kinghorn
Journal:  Curr Drug Targets       Date:  2010-07       Impact factor: 3.465

Review 4.  Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Authors:  Ipsita Pal; Maryam Safari; Marko Jovanovic; Susan E Bates; Changchun Deng
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

5.  Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.

Authors:  U V R Vijaya Saradhi; Sneha V Gupta; Ming Chiu; Jiang Wang; Yonghua Ling; Zhongfa Liu; David J Newman; Joseph M Covey; A Douglas Kinghorn; Guido Marcucci; David M Lucas; Michael R Grever; Mitch A Phelps; Kenneth K Chan
Journal:  AAPS J       Date:  2011-04-16       Impact factor: 4.009

Review 6.  Chemistry and biology of rocaglamides (= flavaglines) and related derivatives from aglaia species (meliaceae).

Authors:  Sherif S Ebada; Neil Lajkiewicz; John A Porco; Min Li-Weber; Peter Proksch
Journal:  Prog Chem Org Nat Prod       Date:  2011

Review 7.  The relevance of higher plants in lead compound discovery programs.

Authors:  A Douglas Kinghorn; Li Pan; Joshua N Fletcher; Heebyung Chai
Journal:  J Nat Prod       Date:  2011-06-08       Impact factor: 4.050

Review 8.  Current status and contemporary approaches to the discovery of antitumor agents from higher plants.

Authors:  Garima Agarwal; Peter J Blanco Carcache; Ermias Mekuria Addo; A Douglas Kinghorn
Journal:  Biotechnol Adv       Date:  2019-01-08       Impact factor: 14.227

9.  Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

Authors:  Janet L Oblinger; Sarah S Burns; Elena M Akhmametyeva; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; Beth Miles-Markley; Aaron C Moberly; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

10.  Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex.

Authors:  Heather Sadlish; Gabriela Galicia-Vazquez; C Gregory Paris; Thomas Aust; Bhupinder Bhullar; Lena Chang; Stephen B Helliwell; Dominic Hoepfner; Britta Knapp; Ralph Riedl; Silvio Roggo; Sven Schuierer; Christian Studer; John A Porco; Jerry Pelletier; N Rao Movva
Journal:  ACS Chem Biol       Date:  2013-05-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.